List of Excipients in Branded Drug CIPROFLOXACIN HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	16590-421	ACETIC ACID
STAT Rx USA LLC	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	16590-421	BENZALKONIUM CHLORIDE
STAT Rx USA LLC	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	16590-421	EDETATE DISODIUM

Generic Drugs Containing CIPROFLOXACIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Blenheim Pharmacal Inc	ciprofloxacin hydrochloride	10544-606	CELLULOSE, MICROCRYSTALLINE
Blenheim Pharmacal Inc	ciprofloxacin hydrochloride	10544-606	COLLOIDAL SILICON DIOXIDE
Blenheim Pharmacal Inc	ciprofloxacin hydrochloride	10544-606	HYPROMELLOSE

What are the Most Frequently-Used Excipients in CIPROFLOXACIN HYDROCHLORIDE?

# Of NDCs	Excipient
1	ACETIC ACID
1	BENZALKONIUM CHLORIDE
6	CELLULOSE, MICROCRYSTALLINE

Ciprofloxacin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Ciprofloxacin hydrochloride is a mature, multisource fluoroquinolone with limited opportunity for conventional active-ingredient exclusivity. Commercial value is concentrated in differentiated dosage forms, pediatric and geriatric usability, ophthalmic and otic delivery, preservative-free packaging, adherence-oriented modified release, and manufacturing cost reduction. The main formulation constraint is ciprofloxacin’s interaction with polyvalent cations, which can reduce absorption when calcium, magnesium, aluminum, iron, or zinc are present.

What is the FDA regulatory status of ciprofloxacin hydrochloride?

Ciprofloxacin hydrochloride is FDA-approved in multiple dosage forms, including immediate-release tablets, extended-release tablets, oral suspension, ophthalmic solution, and otic products. Ciprofloxacin is approved for selected bacterial infections, but its use is limited by fluoroquinolone safety risks and antimicrobial-stewardship policies.

Dosage form	Typical regulatory pathway	Commercial status
Immediate-release tablets	ANDA and legacy NDA products	Highly genericized
Extended-release tablets	NDA/ANDA, depending on product	Smaller but differentiated market
Oral suspension	ANDA and legacy branded products	Pediatric and institutional opportunity
Ophthalmic solution	ANDA and legacy NDA products	Competitive generic market
Otic solution or suspension	ANDA or 505(b)(2), depending on formulation	Niche opportunity
Injectable products	ANDA and legacy NDA products	Hospital and institutional market

FDA labeling warns that oral ciprofloxacin should not be administered with antacids or products containing calcium, magnesium, aluminum, iron, or other polyvalent cations because chelation can reduce systemic exposure.[1] The labeling also carries class warnings for tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis.[1]

The safety profile restricts broad consumer repositioning. Commercial development is more defensible when it improves administration, dosing reliability, storage, or local delivery rather than promoting ciprofloxacin for new systemic indications.

When does ciprofloxacin hydrochloride lose exclusivity?

Ciprofloxacin hydrochloride has lost core compound exclusivity in the United States. The original ciprofloxacin compound and early pharmaceutical patents expired years ago, leaving the market primarily open to generic competition.

The principal exclusivity barriers are now product-specific:

• formulation patents;
• extended-release delivery systems;
• suspension and taste-masking technologies;
• ophthalmic or otic delivery systems;
• manufacturing-process patents;
• device and packaging claims;
• method-of-use patents for narrowly defined infections.

These rights must be evaluated separately from the active ingredient. A company can commercialize ciprofloxacin hydrochloride while facing risk from a formulation or delivery patent, but the existence of a listed patent does not necessarily prevent all generic or alternative dosage forms.

What is the Orange Book status of ciprofloxacin hydrochloride?

The FDA Orange Book lists approved ciprofloxacin products and, where applicable, patent and regulatory-exclusivity information.[2] Immediate-release ciprofloxacin products are generally mature generic products. Product-specific Orange Book entries must be checked by dosage form, strength, applicant, and reference listed drug because tablet, extended-release, ophthalmic, and otic products can have different regulatory and patent profiles.

The Orange Book does not capture every potentially relevant patent. It generally focuses on patents that the NDA holder identifies as covering the approved drug, including active ingredients, formulations, compositions, and methods of use. Manufacturing, packaging, device, and non-listed process rights may require separate freedom-to-operate analysis.

What excipients are used in ciprofloxacin hydrochloride products?

Ciprofloxacin hydrochloride excipients vary by manufacturer and dosage form. Representative excipient classes include:

Excipient class	Typical examples	Primary function
Diluent or filler	Microcrystalline cellulose, lactose, mannitol	Tablet mass and processability
Binder	Povidone, hypromellose	Granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Compression and ejection
Glidant	Colloidal silicon dioxide	Powder flow
Film former	Hypromellose, polyvinyl alcohol	Coating and protection
Suspending agent	Xanthan gum, hypromellose, microcrystalline cellulose combinations	Physical stability
Sweetener	Sucrose, sucralose, sorbitol	Palatability
Flavor	Fruit or citrus flavors	Taste masking
Buffer or pH modifier	Citric acid, sodium citrate, hydrochloric acid, sodium hydroxide	Solubility and stability
Preservative	Methylparaben, propylparaben, benzalkonium chloride	Microbial control
Tonicity agent	Sodium chloride, boric acid, mannitol	Ophthalmic comfort and isotonicity
Chelation-control excipient	None preferred in the systemic formulation	Avoiding reduced absorption

The relevant commercial issue is not whether an excipient is pharmaceutically acceptable in isolation. The issue is whether the complete formulation maintains dissolution, bioavailability, microbial quality, stability, palatability, and manufacturability.

Which excipient interactions create the largest formulation risks?

Polyvalent cation binding

Ciprofloxacin forms poorly absorbed complexes with calcium, magnesium, aluminum, iron, and zinc. This creates a central excipient-screening requirement for oral products.

Formulators should control or exclude:

• calcium salts;
• magnesium salts;
• aluminum-containing antacid materials;
• iron salts;
• zinc salts;
• mineral premixes;
• certain fortified nutritional excipients.

This risk applies particularly to pediatric suspensions, chewable tablets, orally disintegrating tablets, nutritional co-formulations, and combination products.

A product intended for administration with food or nutritional supplements should be evaluated for in-use coadministration, not only in-vitro compatibility. Labeling separation instructions can manage some interaction risk, but they reduce convenience and may impair adherence.

pH and solubility

Ciprofloxacin hydrochloride is a zwitterionic compound with pH-dependent solubility. The formulation must balance dissolution with chemical stability and tolerability. Excessive alkalinity can reduce solubility, while strongly acidic systems may increase irritation or create palatability problems.

For oral suspensions, pH control affects:

• ciprofloxacin solubility;
• sedimentation and redispersibility;
• preservative efficacy;
• flavor performance;
• chemical stability;
• container compatibility.

Preservative compatibility

Multidose oral, ophthalmic, and otic products require microbiological control. Preservatives can create local tolerability concerns, particularly in ocular products used repeatedly or on compromised epithelium.

Preservative-free packaging can provide a stronger commercial proposition than simply changing the preservative. Unit-dose containers, blow-fill-seal packaging, or sterile multidose systems can support premium positioning, although packaging costs rise.

What formulations are protected by ciprofloxacin hydrochloride patents?

The most commercially relevant formulation categories are:

1. Immediate-release oral tablets.
2. Extended-release oral tablets.
3. Dry-powder oral suspensions.
4. Ready-to-use oral suspensions.
5. Ophthalmic solutions.
6. Ophthalmic suspensions.
7. Otic solutions and suspensions.
8. Injectable formulations.
9. Combination products with other anti-infective agents.
10. Device-enabled or preservative-free products.

Legacy ciprofloxacin formulation patents have generally expired or become less commercially significant. Current patent risk is more likely to arise from later-filed claims covering a specific release profile, excipient ratio, particle-size distribution, suspension system, packaging configuration, or local-delivery method.

A strong formulation patent should link the excipient architecture to a measurable technical result, such as:

• improved bioavailability;
• reduced variability;
• sustained release over a defined interval;
• improved redispersibility;
• reduced sedimentation;
• improved taste score;
• lower preservative concentration;
• enhanced ocular residence time;
• improved stability under accelerated conditions.

Broad claims covering routine excipient substitutions are vulnerable to obviousness attacks, especially for a mature generic active ingredient.

How strong is the ciprofloxacin hydrochloride patent estate?

The core patent estate is weak from an exclusivity perspective because the active ingredient is long off-patent and generic competition is extensive. A narrower formulation estate can still have value if it satisfies three conditions:

• the formulation solves a clinically relevant problem;
• the claims are narrow enough to survive prior-art review but broad enough to cover commercial products;
• the product earns a regulatory or market advantage that generic substitution cannot immediately replicate.

Estate category	Relative strength	Commercial implication
Core ciprofloxacin compound	Low	No meaningful new-product exclusivity
Immediate-release tablet composition	Low	Cost and supply-chain competition dominate
Extended-release formulation	Moderate	Potential differentiation if clinical or adherence benefits are demonstrated
Pediatric suspension	Moderate	Taste, stability, and dosing-device claims may create value
Ophthalmic preservative-free product	Moderate	Packaging and tolerability can support a premium
Otic delivery	Moderate	Local-delivery claims may support niche positioning
Manufacturing process	Variable	Can lower cost but may be difficult to enforce
Device and packaging	Variable	Useful for product differentiation, often limited in scope
New method of use	Low to moderate	Depends on clinical evidence and claim specificity

What commercial opportunities exist for ciprofloxacin hydrochloride excipients?

Pediatric oral suspension

Pediatric suspension is one of the clearest excipient opportunities. Ciprofloxacin has a bitter taste, and administration can be difficult when caregivers must separate the dose from mineral-containing food or supplements.

Potential improvements include:

• high-efficiency taste masking;
• reduced sedimentation;
• rapid redispersion after storage;
• lower dosing volume through concentration optimization;
• calibrated oral syringes;
• preservative systems with improved tolerability;
• ready-to-use packaging;
• extended in-use stability;
• excipient systems that avoid polyvalent cations.

A differentiated suspension can target hospitals, outpatient pediatric clinics, specialty pharmacies, and global markets where reconstitution errors affect treatment reliability.

Extended-release tablets

Extended-release ciprofloxacin can reduce dosing frequency and improve adherence. The technical opportunity is to control release without compromising total exposure or creating high peak concentrations.

Relevant excipient systems include:

• hydrophilic matrix polymers;
• hydrophobic matrix formers;
• polymer-coated multiparticulates;
• osmotic or membrane-controlled systems;
• compression-coated tablets.

The main commercial barrier is clinical and regulatory proof. A modified-release product must demonstrate appropriate pharmacokinetics, dissolution performance, dose proportionality where relevant, and bioequivalence or clinical efficacy under the applicable FDA pathway.

Ophthalmic and otic products

Local delivery avoids some systemic exposure concerns and supports targeted product development. Opportunities include:

• preservative-free multidose systems;
• lower-irritation excipient systems;
• enhanced ocular or ear-canal retention;
• reduced dosing frequency;
• suspension systems with uniform dose delivery;
• combination products with anti-inflammatory agents where clinically justified.

For ophthalmic products, sterility, particulate control, container closure integrity, drop size, and preservative exposure are as important as active concentration.

Taste-masked and orally disintegrating products

Taste masking can support use in patients with swallowing difficulties. However, an orally disintegrating or chewable product must be designed around the cation-binding problem. Calcium-containing flavors, mineral excipients, and certain nutraceutical-style ingredients may create avoidable bioavailability risk.

Taste-masking approaches include polymer coating, ion-exchange resins, lipid barriers, cyclodextrin complexes, and multiparticulate encapsulation. Each approach requires assessment of release in the gastrointestinal tract and impact on ciprofloxacin exposure.

Global low-cost manufacturing

The largest near-term opportunity may be operational rather than patent-driven. Ciprofloxacin hydrochloride products can benefit from:

• direct compression;
• lower-cost granulation;
• simplified coating systems;
• high-throughput suspension manufacture;
• reduced solvent use;
• improved powder flow;
• continuous manufacturing;
• lower-cost primary packaging.

Process patents may provide protection, but cost advantages often depend more on scale, supplier qualification, quality systems, and regulatory execution than on exclusivity.

Which companies are challenging ciprofloxacin hydrochloride exclusivity?

Ciprofloxacin is supplied by numerous generic manufacturers and contract manufacturers. Competition varies by country and dosage form. In the United States, major generic-market participants have historically included large manufacturers such as Teva, Sandoz, Viatris, Lupin, Dr. Reddy's Laboratories, Cipla, and Hikma, although applicant participation changes by product and year.

The competitive field includes:

• ANDA applicants for immediate-release tablets;
• specialty manufacturers of ophthalmic and otic products;
• hospital suppliers of injectable products;
• branded-generic companies in emerging markets;
• contract development and manufacturing organizations;
• companies pursuing 505(b)(2) products with delivery or formulation changes.

For a specific product, the relevant competitors are the approved ANDA holders listed in FDA databases, not all companies that manufacture ciprofloxacin in other jurisdictions.

Are there Paragraph IV challenges or settlement agreements?

Paragraph IV litigation is most relevant to later ciprofloxacin products with listed formulation or method-of-use patents. Immediate-release ciprofloxacin tablets are mature products, so current commercial risk is usually driven by price competition rather than a new Paragraph IV event.

A Paragraph IV analysis should review:

• the Orange Book patent list for the reference product;
• ANDA filing dates;
• first-filer status;
• notices of certification;
• district-court complaints;
• patent-term adjustments;
• settlement terms;
• launch dates;
• authorized-generic arrangements.

No general conclusion about an active, product-specific Paragraph IV challenge should be made without identifying the reference listed drug, strength, dosage form, and current Orange Book entry.

What generic launch risks exist for ciprofloxacin hydrochloride?

Generic launch risk is high for standard immediate-release tablets and conventional ophthalmic solutions. The main risks are:

• rapid price erosion;
• multiple approved applicants;
• limited product differentiation;
• wholesaler substitution;
• hospital purchasing pressure;
• active-ingredient supply competition;
• regulatory scrutiny of fluoroquinolone labeling;
• limited physician willingness to pay for minor formulation changes.

Risk is lower for products with operational or clinical differentiation, including:

• preservative-free ophthalmic products;
• stable pediatric suspensions;
• extended-release systems;
• low-volume, high-concentration products;
• products with validated dosing devices;
• formulations supported by a defensible 505(b)(2) strategy.

How does ciprofloxacin hydrochloride compare with competing fluoroquinolones?

Drug	Main formulation opportunity	Generic competition	Key commercial constraint
Ciprofloxacin	Suspension, ophthalmic, otic, extended release	Very high	Safety warnings and cation interaction
Levofloxacin	Ophthalmic, oral, injectable	High	Broad generic substitution
Moxifloxacin	Ophthalmic and oral	High	Limited room for premium pricing
Ofloxacin	Ophthalmic and otic	High	Mature local-delivery market
Gemifloxacin	Oral	Lower availability	Smaller commercial base
Norfloxacin	Ophthalmic and oral in some markets	Mature	Declining clinical use in several regions

Ciprofloxacin retains commercial relevance because of its activity against selected gram-negative pathogens, including Pseudomonas aeruginosa. It also has broad global familiarity and established manufacturing infrastructure. Its disadvantages are extensive generic competition, safety restrictions, and administration complexity caused by mineral interactions.

What licensing deals and partnering opportunities exist?

Licensing value is more likely to arise from technology than from ciprofloxacin hydrochloride itself. Attractive deal assets include:

• taste-masking platforms applicable to pediatric antibiotics;
• preservative-free sterile packaging;
• extended-release oral technology;
• stable suspension systems;
• low-cost continuous manufacturing;
• antimicrobial combination products;
• regional rights for branded generics;
• hospital-focused formulation and packaging systems.

A ciprofloxacin-specific license should be assessed against the breadth of the platform. A narrow patent covering one excipient ratio may have limited value unless the formulation has regulatory approval, supply advantages, or a clear market-access benefit.

Potential transaction structures include:

• regional licensing;
• co-development;
• contract manufacturing with technology transfer;
• supply agreements;
• milestone-based formulation licenses;
• 505(b)(2) development partnerships.

Is there biosimilar risk for ciprofloxacin hydrochloride?

No. Ciprofloxacin hydrochloride is a small-molecule drug, not a biologic. Biosimilar regulation does not apply. Competitive risk comes from generic drugs, authorized generics, branded generics, and differentiated reformulations.

What geographic markets offer the best opportunities?

The United States has high regulatory clarity but intense generic competition. Europe also has mature generic supply and strong price controls. Commercial opportunities may be better in selected emerging markets where:

• pediatric formulations are underdeveloped;
• local manufacturing is favored;
• hospital supply is fragmented;
• branded generics retain market share;
• preservative-free ophthalmic products are limited;
• reliable oral suspensions are scarce.

Geographic patent value is limited for the active ingredient. The principal barriers are regulatory approval, local bioequivalence requirements, manufacturing standards, tender access, trademark rights, and supply reliability.

What manufacturing and intellectual-property barriers matter most?

Manufacturing barriers include:

• control of ciprofloxacin particle size;
• uniformity in low-dose ophthalmic products;
• suspension redispersibility;
• sterile processing;
• preservative efficacy;
• container closure integrity;
• excipient supplier qualification;
• control of polymorphic or hydrate state;
• dissolution reproducibility;
• residual solvent and microbial limits.

The most defensible IP often combines composition, process, and packaging claims. A formulation patent alone may be vulnerable if competitors can achieve the same performance through a different excipient system.

Key Takeaways

• Ciprofloxacin hydrochloride is a mature, off-patent small molecule with high generic competition.
• The main excipient risk is chelation with calcium, magnesium, aluminum, iron, and zinc.
• Pediatric suspension, taste masking, preservative-free ophthalmic products, otic delivery, and extended-release tablets offer the strongest differentiation paths.
• Immediate-release tablets have limited patent and pricing power.
• Formulation patents need measurable technical benefits to be commercially defensible.
• There is no biosimilar risk; generic and branded-generic competition is the relevant threat.
• Licensing value is concentrated in delivery, packaging, manufacturing, and platform technologies.
• Geographic opportunities depend more on regulatory execution, tender access, and supply reliability than on active-ingredient patent rights.

FAQs

Can calcium be used as an excipient in ciprofloxacin hydrochloride tablets?

Calcium-containing excipients create a potential absorption risk for oral ciprofloxacin. They should not be used without a clear justification supported by formulation and pharmacokinetic data.

Is ciprofloxacin hydrochloride suitable for an orally disintegrating tablet?

It can be formulated as an orally disintegrating product, but taste masking, tablet strength, rapid dispersion, and avoidance of mineral excipients are central development requirements.

What is the best premium formulation opportunity for ciprofloxacin?

Preservative-free ophthalmic delivery and a stable, taste-masked pediatric suspension generally offer stronger premium positioning than another immediate-release tablet.

Can a ciprofloxacin suspension be patented today?

A specific suspension may be patentable if it has novelty and non-obvious technical advantages, such as improved stability, redispersibility, taste masking, or dosing consistency. Routine excipient substitution is unlikely to provide strong protection.

Does ciprofloxacin hydrochloride require a 505(b)(2) application?

Not necessarily. Conventional products can generally use the ANDA pathway when they are pharmaceutically equivalent and bioequivalent to an approved reference product. A 505(b)(2) pathway may be relevant for a materially changed delivery system, new indication, or formulation that cannot qualify through an ANDA.

References

1. U.S. Food and Drug Administration. (2024). Ciprofloxacin prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2016). Dissolution testing and specification criteria for generic oral immediate-release solid dosage forms containing high-solubility drug substances. FDA guidance.

4. U.S. Food and Drug Administration. (2018). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA guidance.

5. U.S. Food and Drug Administration. (2016). General principles for evaluating the abuse deterrence of generic solid oral opioid drug products. FDA guidance.

6. U.S. Food and Drug Administration. (2017). Drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics. FDA.

7. DailyMed. (2024). Ciprofloxacin hydrochloride drug labels. National Library of Medicine.